Applications across cancer drug development.

Clyra’s foundation models can be adapted to different biological and clinical-development questions. Patient stratification is one application of the platform, alongside biomarker discovery, response and resistance analysis, and target and indication research.

Patient stratification

Identify molecularly defined patient subgroups associated with survival, progression, response, or other relevant outcomes.

Potential research outputs:

Subgroup definitions

Molecular characteristics

Outcome associations

Trial-enrichment hypotheses

Candidate stratification variables

Biomarker discovery

Prioritize molecular features and signatures associated with tumor state, treatment context, progression, response, resistance, or survival.

Potential research outputs:

Ranked biomarker candidates

Multimodal signatures

Pathway associations

Cross-species concordance

Validation hypotheses

Response and resistance analysis

Examine the biological programs associated with treatment sensitivity, non-response, adaptation, recurrence, and acquired resistance.

Potential research outputs:

Response-associated states

Resistance-associated pathways

Longitudinal state changes

Recurrence patterns

Follow-up analysis hypotheses

Target and indication research

Compare conserved pathways and tumor states to study mechanism, target relevance, and the biological context of potential indications.

Potential research outputs:

Conserved pathway associations

Target-context analysis

Tumor-state prevalence

Indication hypotheses

Translational evidence maps

How an analysis is defined

The scope of an analysis depends on the asset, indication, development stage, available human and canine datasets, and the decision the research is intended to inform. Endpoints and evaluation criteria should be defined before model adaptation begins.

Define the program question

Review available data

Select the appropriate model and endpoints

Evaluate and interpret the findings

Initial work in sarcoma

Clyra is beginning with sarcoma, where biological heterogeneity and limited cohort sizes create a need for additional translational evidence. Comparative analysis is particularly relevant in cancers such as osteosarcoma that occur naturally in both humans and dogs.

The underlying platform is intended for research across additional cancer types as relevant data and validation become available.

Discuss a Program